Synthetic peptides identified from Palmaria palmata enhance glucagon-like peptide-1 stability in vitro and show acute anti-hyperglycaemic and insulinotropic actions in mice

2018/01/01 by C.M. McLaughlin, Chris M. McLaughlin, P.A. Harnedy +11
Medicine · Neuroscience · #Diabetes Treatment and Management #Peptidase Inhibition and Analysis #Neuropeptides and Animal Physiology

paper · pdf · doi:10.1017/s0029665118001210

Abstract

Secretion of the incretin hormone glucagon-like-peptide 1 (GLP-1) from the intestinal L-cells play a significant role in improving glycaemic control following a meal Orally active DPP-4 inhibitor drugs are used to improve glycaemic control in people with diabetes. Several peptide component peptides from the edible seaweed Palmaria palmata (Dulse) have been identified as having DPP-4 inhibitory actions Here we examined the efficacy of three short synthetic peptides derived from Palmaria palmata to stabilise glucagon-like peptide-1(7-36)amide (GLP-1) using an in vitro HPLC assay and to affect insulin secretion and glycaemic control in mice challenged with an intraperitoneal glucose tolerance test (ipGTT).

Related

• Bioactive Peptides Derived from Seaweed Protein and Their Health Benefits: Antihypertensive, Antioxidant, and Antidiabetic Properties
• Glucagon-Like Peptides: Regulators of Cell Proliferation, Differentiation, and Apoptosis
• Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabeticob/obmice
• A novel peptide from Garden pea proteins activates AMP-activated protein kinase and enhances glucose uptake in C2C12 myotubes
• Glucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease